Cynvenio Biosystems, Inc. Announces ClearID, a Breakthrough Test for Monitoring Breast Cancer Patients and Early Detection of Recurrence

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOS ANGELES--(BUSINESS WIRE)--Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in blood, today launched a new weapon in the fight against breast cancer, the ClearID Breast Cancer monitoring program. ClearID Breast Cancer is a high-tech monitoring program that enables the early detection of breast cancer recurrence – a valuable tool that empowers patients to defend their health by actively monitoring for recurrence.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC